![]() ![]() The stock was purchased at an average cost of $50.50 per share, with a total value of $50,500.00. In related news, Director Elizabeth Barrett acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, May 9th. According to, the stock has a consensus rating of “Hold” and an average target price of $51.92. Nine research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Finally, Bank of America lifted their target price on Sage Therapeutics from $61.00 to $66.00 in a report on Thursday, June 15th. HC Wainwright reaffirmed a “neutral” rating and set a $50.00 target price on shares of Sage Therapeutics in a report on Thursday, March 9th. Royal Bank of Canada lifted their target price on Sage Therapeutics from $60.00 to $63.00 in a report on Wednesday, May 3rd. initiated coverage on Sage Therapeutics in a report on Thursday, May 18th. VNET Group reissued a “maintains” rating on shares of Sage Therapeutics in a report on Wednesday, May 3rd. ![]() Several equities research analysts recently weighed in on SAGE shares. will post -8.04 EPS for the current year. On average, sell-side analysts expect that Sage Therapeutics, Inc. The firm’s revenue was up 120.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.07) EPS. The business had revenue of $3.30 million during the quarter, compared to analyst estimates of $2.28 million. Sage Therapeutics had a negative return on equity of 42.32% and a negative net margin of 5,932.09%. The biopharmaceutical company reported ($2.46) EPS for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.04. Sage Therapeutics ( NASDAQ:SAGE – Free Report) last issued its earnings results on Tuesday, May 2nd. Institutional investors own 92.97% of the company’s stock. Finally, Thrivent Financial for Lutherans acquired a new stake in shares of Sage Therapeutics during the 3rd quarter valued at $240,000. ![]() acquired a new stake in shares of Sage Therapeutics during the 2nd quarter valued at $231,000. Neo Ivy Capital Management acquired a new stake in shares of Sage Therapeutics during the 4th quarter valued at $194,000. Exchange Traded Concepts LLC now owns 3,663 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 914 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Sage Therapeutics by 33.2% during the 4th quarter. MetLife Investment Management LLC bought a new position in shares of Sage Therapeutics in the 1st quarter valued at $34,000. Several other hedge funds and other institutional investors also recently modified their holdings of SAGE. owned approximately 0.17% of Sage Therapeutics worth $4,353,000 as of its most recent SEC filing. The fund owned 103,731 shares of the biopharmaceutical company’s stock after purchasing an additional 6,897 shares during the period. ( NASDAQ:SAGE – Free Report) by 7.1% during the 1st quarter, according to the company in its most recent filing with the SEC. grew its holdings in Sage Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |